Clinical Trial Update: A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and immunogenicity of an mRNA-based RSV investigational vaccine in healthy adults aged 18-45. The trial is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV mRNA investigational vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: ACTIVE_NOT_RECRUITING